XNAS
ATYR
Market cap16mUSD
Oct 08, Last price
0.26USD
1D
-8.26%
1Q
-53.10%
Jan 2017
-99.15%
IPO
-99.91%
Name
aTyr Pharma Inc
Chart & performance
P/E
0.23
P/S
0.04
EPS
1.12
Div yield, %
—
Shrs. gr., 5y
46.85%
Rev. gr., 5y
105.97%
Revenues
388m
+164,839.57%
Net income
71m
P
CFO
36m
P
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Ethos Technologies Inc. functions as a third-party administrator for insurance policies in various global markets, including the United States, India, and Singapore. The company offers "Ethos," a comprehensive technology platform designed to transform the process of purchasing, distributing, and overseeing risk for life insurance products among consumers, agents, and insurance providers. Their product portfolio features term, whole, and indexed universal life insurance policies, complemented by offerings such as wills and estate planning assistance, and supplemental health insurance. Ethos serves a broad clientele, encompassing individual consumers, insurance agents, agencies, and carriers. Incorporated in 2016 and based in San Francisco, California, the organization was formerly known as Ethos Insurance Corporation until its name change in August 2016.
Key people
Sanjay S. Shukla
President, Chief Executive Officer, Chief Medical Officer · since 2017
Jill M. Broadfoot
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer · since 2018
Grove Matsuoka
Senior Vice President, Product Programs and Planning · since 2016
Ashraf Amanullah
Vice President, Biologics Development and Manufacturing · since 2015
Melissa A. Ashlock
Vice President - External Scientific Alliances and Human Genetics · since 2011
Holly D. Chrzanowski
Vice President - Enterprise Talent and Organization · since 2013
Andrew Cubitt
Vice President - Product Protection · since 2011
Fred Ramsdell
Vice President - Immunology · since 2014
Jane A. Gross
Director · since 2019
Director · since 2019
John D. Mendlein
Director · since 2017
Independent Director · since 2017
Non-Executive Independent Director · since 2005
Legal address
c/o National Registered Agents, Inc., 160 Greentree DR Suite 101
Dover, DE 19904
US
Dover, DE 19904
US
Headquarters
3545 John Hopkins Court, Suite #250
San Diego, CA 92121
US
San Diego, CA 92121
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||